Aurinia Pharmaceuticals Inc. provided earnings guidance for the fiscal year 2023. For the period, the company is narrowing its net product revenue guidance to a range of $155 million - $160 million for net product sales of LUPKYNIS. This guidance range is based on assumptions regarding PSF run rates, consistent conversion rates, time to convert, persistency and pricing.